Ji Tangrao, Huang Kewei, He Biming, Wang Haifeng
Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, No. 150 Jimo Road, Pudong New District, Shanghai, 200120, China.
Department of Urology, Lanxi People's Hospital, Jinhua, China.
Int Urol Nephrol. 2025 Jan 15. doi: 10.1007/s11255-024-04355-4.
To evaluate the predictive value of Prostate Spherical Volume Ratio for Lower urinary tract symptoms and clinical progression of Benign prostatic hyperplasia. And compared with other prostatic anatomical parameters.
A total of 154 patients with Benign prostatic hyperplasia who underwent MRI and urodynamics were included in the study, while prostate anatomical parameters such as prostate spherical volume ratio, prostate volume, intravesical prostatic protrusion, prostatic urethral length and presumed circle area ratio were determined based on MRI measurements. Average length of follow-up was 12 months. The primary outcome was follow-up for the clinical progression of Benign prostatic hyperplasia, defined as an increase in the International Prostate Symptom Score of at least 4 points, Benign prostatic hyperplasia-related prostatic surgery. Univariate and multivariate linear regression analyses were conducted to identify risk factors for lower urinary tract symptoms. Logistic regression analyses were conducted to identify risk factors for clinical progression of Benign prostatic hyperplasia.
Multivariate linear regression highlighted the significant association of prostate spherical volume ratio with lower urinary tract symptoms. In multivariable logistic regression analysis prostate spherical volume ratio is an independent risk factor for the clinical progression of Benign prostatic hyperplasia to an increase in the International Prostate Symptom Score of at least 4 points (OR = 1.53 p = 0.016) and Benign prostatic hyperplasia -related prostatic surgery (OR = 5.15 p = 0.020).
Prostate spherical volume ratio has been significantly correlated with Lower urinary tract symptoms, and it was an independent risk factor for the clinical progression of Benign prostatic hyperplasia. THIS TRIAL IS REGISTERED ON CLINICALTRIALS.GOV: NCT06448533.
评估前列腺球体积比对于良性前列腺增生患者下尿路症状及临床进展的预测价值，并与其他前列腺解剖学参数进行比较。
本研究共纳入154例接受了MRI检查及尿动力学检查的良性前列腺增生患者，基于MRI测量结果确定前列腺球体积比、前列腺体积、膀胱内前列腺突出度、前列腺尿道长度及假定圆面积比等前列腺解剖学参数。平均随访时间为12个月。主要结局为随访良性前列腺增生的临床进展，定义为国际前列腺症状评分至少增加4分、因良性前列腺增生进行的前列腺手术。进行单因素和多因素线性回归分析以确定下尿路症状的危险因素。进行逻辑回归分析以确定良性前列腺增生临床进展的危险因素。
多因素线性回归突出显示了前列腺球体积比与下尿路症状之间的显著关联。在多变量逻辑回归分析中，前列腺球体积比是良性前列腺增生临床进展至国际前列腺症状评分至少增加4分（OR = 1.53，p = 0.016）及因良性前列腺增生进行前列腺手术（OR = 5.15，p = 0.020）的独立危险因素。
前列腺球体积比与下尿路症状显著相关，且是良性前列腺增生临床进展的独立危险因素。本试验已在ClinicalTrials.gov注册：NCT06448533。
